Fourth quarter 2025 GAAP revenue from continuing operations increased to 568984000, while the company reported a net loss from continuing operations of 3552000, impacted by 28150000 of interest expense and restructuring and impairment-related charges.

Teleflex delivered a strong third quarter, with adjusted operating margin and earnings per share exceeding expectations, and revenue aligning with the midpoint of guidance. The company reported GAAP revenue of $913.0 million, a 19.4% increase year-over-year, and adjusted diluted EPS of $3.67, up from $3.49 in the prior year period. The acquired Vascular Intervention business modestly surpassed its revenue guidance, and integration activities are on track. However, the company recognized significant non-cash impairment charges related to Interventional Urology North America goodwill and the Titan SGS asset group, totaling $403.9 million and $100 million respectively, driven by deteriorating market conditions and lower-than-expected sales growth.

Teleflex delivered a strong second quarter in 2025, with GAAP revenue reaching $780.9 million, a 4.2% increase year-over-year. Adjusted diluted EPS from continuing operations rose to $3.73, up from $3.42 in the prior year. The company also raised its full-year 2025 guidance for both GAAP and adjusted constant currency revenue growth, as well as GAAP and adjusted diluted EPS, primarily driven by the recent acquisition of BIOTRONIK's Vascular Intervention business.

Teleflex reported a decrease in revenue for the first quarter of 2025 compared to the prior year, driven by declines in the EMEA and Asia segments and the OEM product category. Despite this, the company saw growth in Vascular Access, Interventional, Surgical, and Other product categories. GAAP EPS increased significantly while Adjusted Diluted EPS decreased.

Teleflex Incorporated reported Q4 2024 revenue of $795.4 million, up 2.8% year-over-year, with adjusted EPS rising 15.1% to $3.89. GAAP EPS declined to $(2.95) due to a $240 million non-cash goodwill impairment charge. The Interventional and Surgical segments showed strong growth, while Interventional Urology declined. The company reaffirmed its FY25 guidance with expectations for continued revenue growth and adjusted EPS improvements.

Teleflex reported GAAP revenue of $764.4 million, a 2.4% increase compared to the prior year period, and an adjusted diluted EPS of $3.49. The company raised the low end of its full year 2024 adjusted diluted earnings per share from continuing operations guidance from a range of $13.80 to $14.20 to a range of $13.90 to $14.20.

Teleflex reported a 0.9% increase in GAAP revenue to $749.7 million and an adjusted revenue increase of 2.7% to $763.5 million for Q2 2024. The company is raising its revenue and adjusted EPS guidance for the full year, alongside announcing a $500 million share repurchase program.

Teleflex reported first quarter financial results with revenues of $737.8 million, a 3.8% increase compared to the prior year. GAAP diluted EPS from continuing operations was $0.33, while adjusted diluted EPS from continuing operations was $3.21.

Teleflex reported a slight increase in revenue for Q4 2023, but GAAP EPS decreased significantly. Adjusted EPS also saw a minor decrease. The company's full-year revenue grew by 6.6%, and adjusted EPS increased. Teleflex provided 2024 guidance, anticipating revenue growth and a slight increase in adjusted EPS.

Teleflex reported a 5.5% increase in revenues to $743.3 million and an adjusted diluted EPS of $3.41 for the second quarter ended July 2, 2023. The company is raising GAAP revenue growth guidance to 5.80% to 6.55% and maintaining adjusted diluted EPS from continuing operations guidance of $13.00 to $13.60.

Teleflex announced financial results for the first quarter ended April 2, 2023. Revenues were $710.9 million, up 10.8% compared to the prior year period, or up 13.2% on a constant currency basis. GAAP diluted EPS from continuing operations was $1.63, and adjusted diluted EPS from continuing operations was $3.09.

Teleflex reported third quarter revenues of $686.8 million, a decrease of 1.9% year-over-year, but an increase of 2.4% on a constant currency basis. GAAP diluted EPS from continuing operations was $2.16, while adjusted diluted EPS from continuing operations was $3.27.

Teleflex reported Q2 2022 financial results with revenues of $704.5 million, a decrease of 1.3% year-over-year, but an increase of 2.3% on a constant currency basis. GAAP diluted EPS from continuing operations was $2.23, compared to $1.76 in the prior year period, while adjusted diluted EPS from continuing operations was $3.39, compared to $3.35 in the prior year period. The company reduced its full year 2022 revenue growth and earnings per share guidance.

Teleflex Incorporated announced its Q4 2021 financial results, with reported revenues of $761.9 million, a 7.1% year-over-year increase, and adjusted diluted EPS of $3.60, up 10.8% year-over-year. The company provided 2022 guidance, including GAAP revenue growth expected to be 2.3% to 3.8% and adjusted diluted EPS from continuing operations of $13.70 to $14.30.

Teleflex reported strong second-quarter results with a 25.8% increase in revenue to $713.5 million and adjusted EPS of $3.35, up 73.6% year-over-year. The company is maintaining its constant currency revenue guidance and raising its full-year adjusted earnings per share guidance, despite dilution from the respiratory asset sale.

Teleflex reported a slight increase in revenue for Q1 2021, driven by strong performance in the Americas and Asia. Adjusted EPS exceeded expectations due to higher gross and operating margins. The company raised its full-year revenue and adjusted EPS guidance.

Teleflex Incorporated announced its financial results for the fourth quarter and full year ended December 31, 2020. The company's Q4 revenues reached $711.2 million, a 4.4% increase compared to the previous year. However, GAAP diluted EPS decreased by 28.9% to $1.62, and adjusted diluted EPS decreased by 0.9% to $3.25.

Teleflex reported a 3.1% decrease in third quarter revenue to $628.3 million compared to the prior year. GAAP EPS decreased by 49.3% to $2.46, while adjusted diluted EPS decreased by 6.7% to $2.77. The company noted a negative impact of approximately $78 million due to COVID-19.

Teleflex reported a 13.1% decrease in second quarter revenue to $567.0 million compared to the prior year, with a GAAP EPS of $0.24 and adjusted EPS of $1.93. The company's performance exceeded internal expectations due to improvements in underlying monthly revenue trends and prudent operating expense management. Teleflex is not reinstating 2020 financial guidance due to continued uncertainties from the COVID-19 pandemic.

Teleflex reported a 2.8% increase in net revenues to $630.6 million for the first quarter of 2020, with GAAP EPS increasing by 212.4% to $2.78 and adjusted diluted EPS increasing by 21.4% to $2.72. However, due to the uncertainty caused by the COVID-19 pandemic, the company withdrew its previously provided 2020 financial guidance.

Teleflex reported Q4 2019 net revenues of $681.0 million, a 6.1% increase compared to the prior year period. GAAP EPS from continuing operations increased 21.9% to $2.28, and adjusted diluted EPS from continuing operations increased 18.4% to $3.28. The company also announced the acquisition of IWG High Performance Conductors, Inc.